Rubedo's proprietary ALEMBIC drug discovery platform has engineered novel first-in-class small molecules designed to selectively target various types of senescent cells, which play a key role in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic and other chronic disorders. 

The company is headquartered in Sunnyvale, CA, USA.